Research analysts at StockNews.com initiated coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) in a research note issued on Sunday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.
Adamis Pharmaceuticals Price Performance
Shares of ADMP opened at $0.12 on Friday. The business has a fifty day moving average of $0.20 and a 200 day moving average of $0.19. Adamis Pharmaceuticals has a one year low of $0.10 and a one year high of $0.62.
Institutional Investors Weigh In On Adamis Pharmaceuticals
A hedge fund recently raised its stake in Adamis Pharmaceuticals stock. State Street Corp increased its position in Adamis Pharmaceuticals Co. (NASDAQ:ADMP – Get Rating) by 13.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 475,373 shares of the specialty pharmaceutical company’s stock after purchasing an additional 55,168 shares during the quarter. State Street Corp owned approximately 0.32% of Adamis Pharmaceuticals worth $271,000 as of its most recent SEC filing. Institutional investors own 8.57% of the company’s stock.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets.
- Get a free copy of the StockNews.com research report on Adamis Pharmaceuticals (ADMP)
- 3 High Yields On Breakout Watch With Analyst Tailwinds
- Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
- 3 Financials The Insiders Are Buying
- Can Carnival Cruise Lines Set Sail For New Highs?
- If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.